news
1 December 2023
Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies GENOA, Italy, December 1, 2023 — IAMA Therapeutics, a pharmaceutical company focused […]
2 October 2023
GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
13 September 2023
GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
10 July 2023
IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy
GENOA, Italy, July 10, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 June 2023
GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]
31 May 2023
13 January 2023
26 July 2022
29 June 2022
24 May 2022
31 March 2022
